Histologic and clinical outcome after laparoscopic Nissen fundoplication for gastroesophageal reflux disease and Barrett’s esophagus

Özmen, Vahit; Oran, Ebru; Görgün, Emre; Asoğlu, Oktar; İğci, Abdullah; Keçer, Mustafa; Dizdaroğlu, Ferhunde

doi:10.1007/s00464-005-0434-9

Cited by 17 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following laparoscopic antireflux surgery, dysphagia has been reported to significantly improve from preoperative values [47,188,197,198,[200][201][202][203][204] (level II-III). Despite reports of improved dysphagia following surgery, postoperative dysphagia remains a significant problem, with reported reoperation rates ranging from 1.8 to 10.8% [33,34,38,39,143,196,[205][206][207] (level I-III) and endoscopic dilatation rates ranging from 0 to 25% [34,121,143,145,189,195,196,[208][209][210][211][212][213] (level I-III). Although perioperative and early postoperative dysphagia have been reported as high as 76% [191] (level II), the majority of studies show early and mid dysphagia rates, up to 1 year postoperatively, of less than 20% [33,34,38,39,44,47,120,122,189,191,192,195,196,199,200,…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for surgical treatment of gastroesophageal reflux disease

et al. 2010

View full text Add to dashboard Cite

PreambleThe guidelines for the surgical treatment of gastroesophageal reflux disease (GERD) are a series of systematically developed statements to assist physicians and patient decisions about the appropriate use of laparoscopic surgery for GERD. The statements included in this guideline are the product of a systematic review of published literature on the topic, and the recommendations are explicitly linked to the supporting evidence. The strengths and weaknesses of the available evidence are highlighted and expert opinion sought where the evidence is lacking. This is an update of previous guidelines on this topic (last revision 06/2001) as new information has accumulated. DisclaimerGuidelines for clinical practice are intended to indicate preferable approaches to medical problems as established by experts in the field. These recommendations will be based on existing data or a consensus of expert opinion when little or no data are available. Guidelines are applicable to all physicians who address the clinical problem(s) without regard to specialty training or interests, and are intended to indicate the preferable, but not necessarily the only, acceptable approaches due to the complexity of the healthcare environment. Guidelines are intended to be flexible. Given the wide range of specifics in any health care problem, the surgeon must always choose the course best suited to the individual patient and the variables in existence at the moment of decision.Guidelines are developed under the auspices of the Society of American Gastrointestinal and Endoscopic Surgeons and its various committees, and approved by the Board of Governors. Each clinical practice guideline has been systematically researched, reviewed, and revised by the guidelines committee, and reviewed by an appropriate multidisciplinary team. The recommendations are therefore considered valid at the time of its production based on the data available. Each guideline is scheduled for periodic review to allow incorporation of pertinent new developments in medical research knowledge, and practice. Literature review methodWe identified 448 relevant articles. The abstracts were reviewed by four committee members (D.S., W.W.H., P.R.R., G.P.K.) and divided into the following categories:(a) Randomized studies, metaanalyses, and systematic reviews (b) Prospective studies (c) Retrospective studies (d) Case reports (e) Review articles Randomized controlled trials, metaanalyses, and systematic reviews were selected for further review, along with prospective and retrospective studies that included at least 50 patients. Studies with smaller samples were considered when additional evidence was lacking. The most recent reviews were also included. All case reports, older reviews, and smaller studies were excluded. According to these exclusion criteria, 227 articles were reviewed. Whenever the available evidence from level I studies was considered to be adequate, lower evidence level studies were not considered. A review of the available evidence on endoluminal treatment of...

show abstract

Section: Discussionmentioning

confidence: 99%

“…Antireflux surgery does not change these recommended surveillance guidelines. Furthermore, there is no evidence indicating that surveillance is more difficult or less effective after antireflux surgery [210,216,247,292,293].…”

Section: Surveillance Of Barrett's Esophagus After Antireflux Surgerymentioning

confidence: 97%

Guidelines for surgical treatment of gastroesophageal reflux disease

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Recently, a variety of endoluminal procedures have been developed in an effort to treat GERD symptoms and reduce or eliminate the use of antisecretory medication [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]. One procedure involves the delivery of a transmural suture in the anterior gastric cardia to create a full-thickness tissue plication to recreate the valvular mechanism of the gastroesophageal (GE) junction (Plicator Ò ; former distributor NDO Surgical, Inc., Mansfield, MA, USA; current product of Ethicon Endosurgery, Sommerville, NJ, USA).…”

mentioning

confidence: 99%

Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease using multiple Plicator implants: 12-month multicenter study results

Renteln

Schiefke

Fuchs³

et al. 2009

Surg Endosc

View full text Add to dashboard Cite

show abstract

“…Not surprisingly, as many as 25% of patients that come to anti-reflux surgery have BE [102][103][104]. While anti-reflux surgery and elimination of reflux may have a beneficial effect on neoplastic progression of disease, treatment of the BE segment with RFA safely and effectively eliminating BE now provides an additional tool for the surgeon.…”

Section: Role Of Surgery and Radiofrequency Ablationmentioning

confidence: 99%

The Case for Endoscopic Treatment of Non-dysplastic and Low-Grade Dysplastic Barrett’s Esophagus

et al. 2010

View full text Add to dashboard Cite

Non-dysplastic mucosa (ND-) in Barrett's esophagus (BE) shows clonal molecular aberrations, loss of cell cycle control, and other features of "neoplasia." These changes occur prior to morphologic expression of neoplasia (dysplasia). Morphologic evaluation of dysplasia is fraught with error, and, as a result, often leads to false-negative and false-positive diagnoses. Early "crypt dysplasia" is difficult to detect, and is often missed in routine biopsy specimens. Some studies show substantial progression rates of low-grade dysplasia (LGD), and crypt dysplasia, to esophageal adenocarcinoma (EAC). Dysplasia, even when fully developed, may, in certain circumstances, be difficult to differentiate from non-dysplastic (regenerating) BE. Radiofrequency ablation (RFA) is a safe and effective method for removing mucosa at risk of cancer. Given the difficulties of dysplasia assessment in mucosal biopsies, and the molecular characteristics of ND-BE, this technique should be considered for treatment of all BE patients, including those with ND or LGD. Post-ablation neo-squamous epithelium reveals no molecular abnormalities, and is biologically stable. Given that prospective randomized controlled trials of ablative therapy for ND-BE aiming at reducing EAC incidence and mortality are unlikely to be completed in the near future, endoscopic ablation is a valid management option. The success of RFA in achieving safe, uniform, reliable, and predictable elimination of BE allows surgeons to combine fundoplication with RFA. Currently, there is no type of treatment for dysplastic or non-dysplastic BE that achieves a complete response in 100% of patients, eliminates all risk of developing cancer, results in zero adverse events, is less expensive in terms of absolute costs than surveillance, is durable for 20+ years, or eliminates the need for surveillance. Regardless, RFA shows established safety, efficacy, durability, and cost-effective profiles that should be considered in the management of patients with non-dysplastic or low-grade dysplastic BE.

show abstract

Histologic and clinical outcome after laparoscopic Nissen fundoplication for gastroesophageal reflux disease and Barrett’s esophagus

Abstract: Laparoscopic Nissen fundoplication effectively controls intestinal metaplasia and clinical symptoms in the majority of patients with Barrett's esophagus.

Cited by 17 publications

References 20 publications

Guidelines for surgical treatment of gastroesophageal reflux disease

Guidelines for surgical treatment of gastroesophageal reflux disease

Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease using multiple Plicator implants: 12-month multicenter study results

The Case for Endoscopic Treatment of Non-dysplastic and Low-Grade Dysplastic Barrett’s Esophagus

Contact Info

Product

Resources

About